HENDERSON, NV–(Marketwired – Nov 28, 2016) – mCig, Inc., ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today its VitaCig Division continuing its international expansion by securing a three year distribution agreement for Europe with a minimum purchase of $2M over the next three years.
Fresh off the heels of closing a $1.3M three-year contract for Japan, the VitaCig Division has closed yet again another lucrative international contract, this time for the European Union, including Russia.
CEO Paul Rosenberg comments, “I am extremely pleased to announce our agreement with Mr. Jozsef Fuzesi, CEO of Nefeloma Trade LTD for the distribution and sale of our premier VitaCig line of products in both Europe and Russia. Focusing on international expansion is a key path for long term growth and success.”
New VitaCig International Partner, Mr. Jozsef Fuzesi, comments, “I am extremely excited about the new partnership with mCig and VitaCig, the maker of the original Vitamin Vaporizer. I am honored to have the ability to offer a healthier alternative to tar and tobacco based products, and taking into consideration the overwhelming initial interest, we are looking forward to a very lucrative partnership.”
With this contract, mCig continues to add to its IP and asset portfolio with VitaCig mark now protected in Europe and Russia.
Lastly mCig/VitaCig is pleased to announce the launch of its VitaCig® Excalibur Rechargeable Capsule System. Delivering the next generation of VitaCig inhalation science and technology, the VitaCig® Excalibur features a unique, advanced twist on pre-filled capsule design. Producing an even smoother, rich, dense vapor than its disposable counterpart, along with its sleek, classy design, the VitaCig® Excalibur is the perfect extended pleasure at home, on the go, or with some friends. The VitaCig® Excalibur kit comes with the battery bottom, two pre-filled capsules, one Marvelous Mint, one Boisterous Berry, and an innovative chargeable USB Adapter. The pre-filled flavor capsule liquid is enriched with all the vitamins, essential oils, and natural plant extracts associated with the VitaCig® disposable device. Aromatherapy on the go!
The VitaCig® Excalibur advanced capsule system was created to appeal not just to the beginner vape/e-cig user, as with our VitaCig® disposable product, but also to the moderate user who prefers more of the open tank vaporizers. Keeping with innovation and convenience, our tank capsule system are pre-filled, so there is no mess or waste.
In addition to the VitaCig® Excalibur, with the Holiday shopping season in full swing, VitaCig has also released its Candy Cane — Special Holiday Limited Edition VitaCig®. Both the VitaCig® Excalibur and our new VitaCig® Candy Cane Holiday Edition make for the perfect gift or stocking stuffer. For more information visit http://www.vitacig.org/
Stay tuned for future updates!
About mCig, Inc.
Headquartered in Henderson, Nevada, mCig, Inc. ( OTCQB : MCIG ) A diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. MCIG has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Scalable Solutions division currently operating in the rapidly expanding Nevada market. The company looks forward to growing its core competencies to service the Ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. For more information visit www.mcig.org.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.